SEARCH

SEARCH BY CITATION

References

  • 1
    European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:22742.
  • 2
    British Medical Association. British National Formulary (BNF), No. 57. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2009.
  • 3
    Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:100110.
  • 4
    Leung N, Peng CY, Sollano J, et al. Entecavir (ETV) results in higher HBV-DNA reduction vs adefovir (ADV) in CHRONICALLY Infected HBeAg+ antiviral-naïve adults: 48 week results (E.A.R.L.Y. Study). Podium presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver April 11–15, 2007 Barcelona, Spain. 2007, Oral No. 49.
  • 5
    Yao G, Chen C, Lu W, et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients. J Hepatol 2006;449(Suppl. 2):S193.
  • 6
    Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:74554.
  • 7
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:257688.
  • 8
    Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:52836.
  • 9
    Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston MA, November 2–6 2007. 2007, Abstract No LB6.
  • 10
    Marcellin P, Buti M, Krastev Z, et al. A Randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston MA, November 2–6. 2007, Abstract No LB2.
  • 11
    Dienstag JL, Wei LJ, Xu D, et al. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007;27:3549.
  • 12
    Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:95664.
  • 13
    Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897900.
  • 14
    Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:119.
  • 15
    Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:310524.
  • 16
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008. Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf[Accessed July 22, 2010.
  • 17
    Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil in the treatment of chronic hepatitis B. Value Health 2010;13:In press.
  • 18
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:80816.
  • 19
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:8007.
  • 20
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:268295.
  • 21
    Gilead Sciences. Study GS-US-174-0103. A randomised, double-blind, controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of HBeAg positive chronic hepatitis B. Clinical study report, Gilead Sciences, data on file. 2007.
  • 22
    Gilead Sciences. Study GS-US-174-0102: A randomized, double-blind, controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant hepatitis B. Clinical study report, Gilead Sciences, data on file. 2007.
  • 23
    Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:68391.
  • 24
    Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1134.iii–iv.
  • 25
    The BUGS Project. Bayesian inference using Gibbs Sampling (BUGS). WinBUGS with DoodleBUGS version 1.4. Cambridge/London, UK, 2003–7.
  • 26
    Multi-Parameter Evidence Synthesis Research Group Bristol University. Mixed treatment comparisons. 2008. Available from: https://www.bris.ac.uk/cobm/research/mpes/mtc.html[Accessed June 22, 2010.
  • 27
    Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;101:44759.
  • 28
    Cooper NJ, Sutton AJ, Lu G, et al. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166:126975.
  • 29
    Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med 2002;21:160123.
  • 30
    Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:268599.
  • 31
    Goubar A, Ades AE, De Angelis D, et al. Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data. J R Stat Soc A 2008;171:54180.
  • 32
    Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:31223.
  • 33
    Lai C-L, Gane E, Liaw YF, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial. Hepatology 2005;42:748A.
  • 34
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998;339:618.
  • 35
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:125663.
  • 36
    Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study on lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week 52 analysis [abstract]. J Hepatol 2003;38:256.
  • 37
    Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:81826.
  • 38
    GlaxoSmithKline UK. NUC20905: a multicentre, double-blind, randomised, placebo-controlled pilot study to evaluate the effect of lamivudine on serum HDV RNA in subjects co-infected with hepatitis B and delta virus. Summary of clinical trial. 2005.
  • 39
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:101120.
  • 40
    Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:203949.
  • 41
    Yurdaydin C, Sollano J, Hadziyannis S, et al. Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg (+) chronic hepatitis B patients (ETV-026). Liver Int 2006;26:14.
  • 42
    Yurdaydin C, Sollano J, Hadziyannis S, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). J Hepatol 2005;449(Suppl. 2):S36.
  • 43
    Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91101.
  • 44
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:8190.
  • 45
    Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198209.
  • 46
    Colonno R, Rose R, Cross A, et al. Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study AI463-014. J Hepatol 2004;40(Suppl. 1):S16.
  • 47
    Chang TT, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine [abstract]. Hepatology 2002;36:300a.
  • 48
    BMS. Study AI463052, BMS-200475. Available from: http://ctr.bms.com/pdf//AI463052.pdf[Accessed July 22, 2010.
  • 49
    Marzano A, Gaia S, Barbon V, et al. Therapy with adefovir alone or combined with lamivudine in patients with lamivudine-resistant chronic hepatitis B: clinical and virological aspects. Hepatology 2006;44:231a.
  • 50
    Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:111016.
  • 51
    Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:118592.
  • 52
    Berg T, Moeller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). Podium presentation #1219 at the 2008 European Association for the Study of the Liver conference, 2008.
  • 53
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. New Engl J Med 2008;359:244255.
  • 54
    Mellerup MT, Krogsgaard K, Mathurin P, et al. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2005;3:CD000345.
  • 55
    Hui AY, Chan HL, Cheung AY, et al. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005;22:51928.
  • 56
    Rudin D. Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials. Adv Ther 2007;24:78495.
  • 57
    Rudin D, Shah SM, Kiss A, et al. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007;27:118593.
  • 58
    Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007;13:42647.
  • 59
    Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:44754.
  • 60
    National Institute for Health and Clinical Excellence. NICE technology appraisal guideance 173. Tenofovir disoproxil for the treatment of chronic hepatitis B. 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/TA173Guidance.pdf[Accessed July 22, 2010.
  • 61
    Van Bommel F, Mauss S, Wunsche T, et al. No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years. Hepatology 2006;44(Suppl. 1):A549.
  • 62
    Leemans WF, Janssen HL, De Man RA. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007;13:255467.
  • 63
    Bowden DS, Thompson AJ. New developments in HBV molecular diagnostics and quantitative serology. Hepatol Int 2008;2(Suppl. 1):S311.
  • 64
    Dai CY, Yu ML, Chen SC, et al. Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J Clin Pathol 2004;57:1415.
  • 65
    Gilbert N, Corden S, Ijaz S, et al. Comparison of commercial assays for the quantification of HBV DNA load in health care workers: calibration differences. J Virol Methods 2002;100:3747.
  • 66
    Gilead Sciences. Adefovir dipivoxil for the treatment of chronic hepatitis B. Manufacturer submission to NICE, 2005.
  • 67
    Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006;10:1183. iii–iv, xi–xiv.
  • 68
    Sollano J, Schiff E, Carrilho F, et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. Hepatology 2004;40:665a.
  • 69
    Gish RG, De Man R, Pedersen C, et al. Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naive, HBeAg(+) patients: 24-week follow-up results of phase 3 study ETV-022. J Hepatol 2005;42(Suppl. 2):177.
  • 70
    Chang TT, Gish R, De Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV- 022 in nucleoside-naive patients. Hepatology 2004;40:193a.
  • 71
    Leung N, Peng CY, Sollano J, et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBEAG (plus) antiviral-naive adult: 24 wk results (E.A.R.L.Y. study). Hepatology 2006;44:554a.
  • 72
    Bzowej N, Chan HLJ, Lai CL, et al. A randomized trial of telbivudine (LDT) vs. adefovir for HBEAG-positive chronic hepatitis B: final week 52 results. Hepatology 2006;44:563a.
  • 73
    Gane E, Lai CL, Liaw YF, et al. Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: efficacy, safety, and predictors of response at 1 year. J Hepatol 2005;44(Suppl. 2):S1834.
  • 74
    Di Bisceglie A, Lai C-L, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Podium presentation at the AASLD Annual Meeting October 27–31 2006, Boston, MA. 2006, Abstract No. 112.
  • 75
    Lai CL, Leung NWY, Teo EK, et al. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patiens with chronic hepatitis B [AASLD abstract]. Hepatology 2003;38:262a.
  • 76
    Lai CL, Leung N, Teo EK, et al. International multicenter trial of LDT (telbivudine), alone and in combination with lamivudine, for chronic hepatitis B: an interim analysis [abstract]. Hepatology 2002;36:301a.
  • 77
    Yao G, Chen CW, Lu WL, et al. Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2-year results from a phase 3 study in nucleoside-naive patients in China. Hepatology 2006;44:559a.